Меню
Набор скоро начнётся NCT07084298

Effects of Iron Supplementation on Skeletal Muscle Properties in Females With Suboptimal Iron Storage

Ранняя фаза I С лечением Iron Deficiency

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
В протоколе указаны: Oral iron supplement, Placebo.
Кому может быть актуально
Состояния в реестре: Iron Deficiency. Базовые параметры: 18 лет — 40 лет · Женщины.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
Канада
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →
Официальное название

Effects of 12 Weeks of Oral Iron Supplementation on Skeletal Muscle Iron Content, Mitochondrial Function, and Indices of Aerobic Fitness in Healthy Females With Suboptimal Iron Stores

Обзор

The goal of this clinical trial is to learn whether oral iron supplementation will increase skeletal muscle iron storage and its effects on exercise capacity in females with suboptimal iron status. The study will include healthy females, ages 18-40, who either have suboptimal or optimal iron stores. The main questions it aims to answer are: * Does iron supplementation increase skeletal muscle iron storage and alter the expression of iron-related and mitochondrial proteins? * Does iron supplementation improve single-leg exercise performance? * Is serum ferritin correlated with the abundance of iron-related proteins in skeletal muscle? Researchers will compare outcomes from females with suboptimal iron status who receive oral iron supplementation to those who receive a placebo to see if supplementation improves muscle iron storage, protein expression, and exercise performance. Additionally, a non-intervention control group with optimal iron status will be included to assess baseline differences. Participants will: \- Be randomly assigned to receive 150 mg elemental iron or placebo (maltodextrin) every other day for 12 weeks Complete pre- and post-supplementation testing, including: * Blood draws to assess iron status * Skeletal muscle biopsies to analyze protein content * Whole-body and single-leg exercise tests to assess performance * Controls will undergo baseline-only testing to compare physiological and biochemical markers

Подробное описание

This study is intended to evaluate the effects of oral iron supplementation on muscle iron levels in females with suboptimal iron status. The design involves both a randomized controlled trial (RCT) for those with low blood iron levels, as well as a cross-sectional component, including only healthy controls. Iron supplementation will be administered to half of those enrolled in the RCT portion to evaluate the effects of iron uptake within the muscle. Therefore, the primary goal of the study is to determine if iron is stored within the muscle in meaningful amounts following an extended period of oral iron supplementation in healthy females with suboptimal iron status.

The study's rationale extends from the high prevalence of low iron levels among females globally, especially among those who are involved in endurance sports. At the level of the muscle, iron serves in several key biological functions, including oxygen transport, energy production, and even recovery from exercise, making it essential for performance. Although the investigators understand some amount of iron is stored within the muscle, the investigators are currently unaware whether meaningful changes occur following a period of supplementation. Therefore, the proposed protocol outlined below is designed to test the hypothesis that taking iron for a prolonged period at adequate doses will result in meaningful changes.

Participants involved in this study will include biological females aged 18-40 with suboptimal iron status (blood ferritin ≤50 µg/L), who are otherwise healthy, for the RCT portion, or normal iron status (blood ferritin ≥50 µg/L) for healthy controls. Interested participants will be screened, and those eligible for the RCT will be randomly assigned to either an oral iron supplement or a placebo sugar pill, ensuring that the encapsulation is preserved to promote blinding. Participants will consume the assigned treatment once every 2nd day for 12 weeks. Exercise and other biological tests will be performed both before and after supplementation during the RCT, while healthy controls will only participate in baseline testing.

The following is an overview of the study design:

Baseline testing

This phase involves five visits and approximately 6.5 hours of laboratory testing spread over two weeks. Participants in the RCT and those acting as healthy controls will both complete the baseline testing phase.

Visit I: Blood draw

Participants will report to the laboratory in the fasted condition. They will be verbally informed of the methods of this study by the researcher and given time to ask questions before their written consent is obtained. Participants will complete a short survey to characterize their menstrual cycle. Subsequently, an individual trained in phlebotomy will collect venous blood for analysis from an antecubital vein using appropriate techniques. Following analysis of the blood iron markers, participants will be informed whether they are eligible to participate in the RCT or serve as a control. This visit will take approximately 1 hour.

Visit II: Body composition scan and familiarization

Participants will arrive fasted and undergo a body composition scan via dual-energy x-ray absorptiometry (DXA), which takes approximately 10 minutes. They will then be permitted to eat and drink. Participants will complete additional questionnaires (to be repeated before each exercise testing session) detailing perceived rest and food records. They will then be familiarized with a dynamic knee extension (i.e., kicking) task involving 15 minutes of exercise at varying intensities with feedback on technique. Once familiarized, participants will perform a single-leg incremental ramp protocol to determine their quadriceps peak power. In this test, participants will kick at a fixed cadence (e.g., 40 kicks per minute) while resistance gradually increases until they are unable to continue due to fatigue or personal choice. This test will last approximately 10 to 20 minutes. This visit will take approximately 1.5 hours.

Visit III: V̇O₂max and familiarization

On a separate day, at least 24 hours after the last visit, participants will return to the lab without fasting. They will complete an incremental ramp exercise test on a cycle ergometer (double-leg) to measure V̇O₂max, characterizing their aerobic fitness. This test involves gradually increasing resistance until the participant can no longer continue. After a rest period of at least 20 minutes (or longer if needed), participants will perform additional familiarization with the dynamic knee extension exercise, consisting of 30 minutes of kicking at various intensities. This visit will take approximately 1.5 hours.

Visit IV: Lower-body power, quadriceps oxidative capacity, and critical power

On a separate day, at least 24 hours after their last visit, participants will return to the lab without fasting. During this visit, participants will perform countermovement jumps and undergo testing of quadriceps oxidative capacity (OxCap) and critical power (CP) in their dominant leg. They will begin with OxCap testing, which involves a brief isometric contraction of the knee extensor muscles followed by repeated short arterial occlusions using a rapid cuff inflator. This test is performed in duplicate. Next, participants will perform countermovement jumps - a series of vertical jumps on a force plate repeated three times with 60-second rests in between. After resting for 10 to 15 minutes, they will perform three bouts of dynamic knee extension at different intensities to task failure to determine CP. Each bout will last 2 to 20 minutes and be separated by at least 20 minutes of rest. This visit will take approximately 2 hours.

Visit V: Muscle biopsy procedure

On a separate day, at least 24 hours after their last visit, participants will return to the lab in a fasted state for a muscle biopsy. A physician will obtain a small muscle sample using the proper technique, which will later be analyzed for iron-related and mitochondrial protein content. This visit will take approximately 45 minutes.

Supplementation phase

This phase involves two visits and approximately one hour of laboratory testing. Only participants in the RCT will complete this phase.

Participants in the RCT will be randomized to receive either an iron supplement or a placebo in a 1:1 ratio using a concealed allotment procedure. Participants will consume either one iron pill (150 mg elemental iron) or one placebo pill (PolyCal, maltodextrin) every other day for 12 weeks. Each iron supplement contains 50 mg of elemental iron, while the placebo includes none. This dosing protocol is based on prior research showing that alternate-day dosing improves gastrointestinal tolerance. Both iron and placebo pills will be encapsulated within a gelatin capsule for blinding, ensuring no difference in release rate.

Visits VI and VII: Week 4 and 8 blood draws

Participants will visit the lab during weeks 4 and 8 of their supplementation period to provide blood samples. Before each blood draw, they will complete questionnaires about gastrointestinal symptoms and a food record covering the previous three days. Blood will be collected by a trained individual using a standard venipuncture technique. Each visit will take approximately 30 minutes.

Post-supplementation testing

Post-supplementation testing will involve the same procedures as baseline testing, but the visits will be slightly more condensed and re-ordered. In total, participants will visit the lab three times over approximately two weeks for about 5.5 hours of testing. Only RCT participants will complete this phase.

Visit VIII: Blood draw, muscle biopsy, and body composition scan.

After completing supplementation, participants will return to the lab in a fasted state to provide a blood sample and a muscle biopsy, and to undergo a body composition scan. Participants will also repeat familiarization with the single-leg exercise task, using the same procedure from visit II. They will complete questionnaires on gastrointestinal symptoms and their three-day food record. This visit will take approximately 2 hours.

Visits IX and X: Exercise testing

These visits are identical to visits III and IV from the baseline phase and will take the same amount of time (1.5 and 2 hours, respectively) over approximately one week. They will begin a minimum of 48 hours after visit VIII and be separated by at least 24 hours. Before each test, participants will complete questionnaires about rest and their food records for the preceding three days. After all testing is complete, participants and researchers will record their guess about which supplement was consumed to assess the effectiveness of blinding. Participants will then be informed of their group allocation.

Вмешательства

  • Пищевая добавка Oral iron supplement
    Encapsulated ferrous sulphate (150mg elemental iron)
  • Другое Placebo
    Encapsulated polysaccharide (maltodextrin)

Первичные конечные точки

  • Muscle Ferritin [Срок оценки: At baseline (week 0) and completion of supplementation (week 12)]
Вторичные конечные точки (7)
  • Serum iron status [Срок оценки: Every four weeks beginning at baseline (week 0) until completion of supplementation (week 12)]
  • Iron-related proteins [Срок оценки: At baseline (week 0) and completion of supplementation (week 12)]
  • Mitochondrial proteins [Срок оценки: At baseline (week 0) and completion of supplementation (week 12)]
  • Whole body aerobic fitness (VO2max) [Срок оценки: At baseline (week 0) and completion of supplementation (week 12)]
  • Single-leg critical power [Срок оценки: At baseline (week 0) and completion of supplementaton (week 12)]
  • Muscle oxidative capacity [Срок оценки: At baseline (week 0) and completion of supplementation (week 12)]
  • Countermovement jump test [Срок оценки: At baseline (week 0) and completion of supplementation (week 12)]

Критерии участия

Критерии включения

  • biologically female
  • between the ages of 18-40 years of age at the time of enrolment
  • plasma ferritin ≤ 50 µg/ L (RCT) or >50 µg/L (controls)
  • complete Get Active Questionnaire (GAQ: Canadian Society for Exercise Physiology) without contraindication

Критерии исключения

  • have a body mass index (BMI) > 30 kg/m2
  • taking medications that have been shown to affect cardiovascular, respiratory, or metabolic responses to exercise (e.g., β-blockers, anti-inflammatories, anti-coagulants, insulin, etc.)
  • hemoglobin ≤ 120 g/L (anemia cut-off for women)
  • have known health problems or contraindications that prohibit exercise, including renal or gastrointestinal disorders, metabolic disease, heart disease, vascular disease, arthritis, diabetes, respiratory disease, uncontrolled blood pressure, dizziness, thyroid problems, or any other health conditions that are being treated and deemed likely to confound the results
  • dieting for weight loss or following a low-carbohydrate diet (known to affect iron homeostasis)
  • history of smoking or using tobacco products
  • consuming excessive amounts of alcohol (>21 units/week)
  • supplementing with iron (>5mg/day) in the last 3 months
  • any blood donation or surgeries in the past 3 months
  • antibiotic use within the previous four weeks before study enrolment
  • current laxative use
  • known history of thalassemia
  • known bleeding disorder
  • chronic use of nonsteroidal anti-inflammatory drugs
  • Currently/last 3 months taking prescription medications that are known to affect iron absorption (i.e. Antacids/PPIs (e.g., omeprazole), H2 Blockers (e.g., ranitidine), Tetracycline Antibiotics (e.g., doxycycline), Quinolone Antibiotics (e.g., ciprofloxacin), Cholestyramine, Colchicine, Methyldopa).
  • currently pregnant or plans to get pregnant within the duration of the study, and
  • do not understand English
  • Participants will be removed from the study if they begin taking any other forms of supplemental iron or choose to donate blood

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Да

Дизайн исследования

Распределение
Рандомизированное
Модель
Параллельные группы
Маскирование
Тройное слепое
Основная цель
Фундаментальное исследование

Центры проведения

Канада · 1 центр
  • University of Calgary — Calgary

Публикации

  • Rineau E, Gueguen N, Procaccio V, Genevieve F, Reynier P, Henrion D, Lasocki S. Iron Deficiency without Anemia Decreases Physical Endurance and Mitochondrial Complex I Activity of Oxidative Skeletal Muscle in the Mouse. Nutrients. 2021 Mar 24;13(4):1056. doi: 10.3390/nu13041056. PMID 33805065
  • Paul BT, Manz DH, Torti FM, Torti SV. Mitochondria and Iron: current questions. Expert Rev Hematol. 2017 Jan;10(1):65-79. doi: 10.1080/17474086.2016.1268047. Epub 2016 Dec 12. PMID 27911100
  • Ohira Y, Hegenauer J, Strause L, Chen CS, Saltman P, Beinert H. Mitochondrial NADH dehydrogenase in iron-deficient and iron-repleted rat muscle: an EPR and work performance study. Br J Haematol. 1982 Dec;52(4):623-30. doi: 10.1111/j.1365-2141.1982.tb03938.x. PMID 6291576
  • Moretti D, Goede JS, Zeder C, Jiskra M, Chatzinakou V, Tjalsma H, Melse-Boonstra A, Brittenham G, Swinkels DW, Zimmermann MB. Oral iron supplements increase hepcidin and decrease iron absorption from daily or twice-daily doses in iron-depleted young women. Blood. 2015 Oct 22;126(17):1981-9. doi: 10.1182/blood-2015-05-642223. Epub 2015 Aug 19. PMID 26289639
  • MacInnis MJ, Zacharewicz E, Martin BJ, Haikalis ME, Skelly LE, Tarnopolsky MA, Murphy RM, Gibala MJ. Superior mitochondrial adaptations in human skeletal muscle after interval compared to continuous single-leg cycling matched for total work. J Physiol. 2017 May 1;595(9):2955-2968. doi: 10.1113/JP272570. Epub 2016 Aug 3. PMID 27396440
  • Jacobs A. Tissue changes in iron deficiency. Br J Haematol. 1969 Jan-Feb;16(1):1-4. doi: 10.1111/j.1365-2141.1969.tb00372.x. No abstract available. PMID 5795211
  • Hinton PS, Giordano C, Brownlie T, Haas JD. Iron supplementation improves endurance after training in iron-depleted, nonanemic women. J Appl Physiol (1985). 2000 Mar;88(3):1103-11. doi: 10.1152/jappl.2000.88.3.1103. PMID 10710409
  • Frise MC, Holdsworth DA, Johnson AW, Chung YJ, Curtis MK, Cox PJ, Clarke K, Tyler DJ, Roberts DJ, Ratcliffe PJ, Dorrington KL, Robbins PA. Abnormal whole-body energy metabolism in iron-deficient humans despite preserved skeletal muscle oxidative phosphorylation. Sci Rep. 2022 Jan 19;12(1):998. doi: 10.1038/s41598-021-03968-4. PMID 35046429

Идентификаторы

NCT: NCT07084298 · REB25-0927

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗